反应详情

Prepared in 65% yield from (S)-methyl 2-(5-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2′,4′-difluoro-6′-((S)-pent-4-en-2-yloxy)-[1,1′-biphenyl]-3-yl)-7-methylimidazo[1,2-a]pyridin-6-yl)-2-(tert-butoxy)acetate following the same procedure as methyl(2S)-2-(tert-butoxy)-2-[(22S)-18-fluoro-4,22,28-trimethyl-21,27-dioxa-1,7,34-triazahexacyclo[26.2.2.16,9.110,14.02,7.015,20]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate. 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J=8.0 Hz, 1H), 8.01 (s, 1H), 7.79 (s, 1H), 7.72 (dd, J=5.6, 3.4 Hz, 1H), 7.58-7.49 (m, 1H), 7.33 (s, 1H), 6.63-6.49 (m, 2H), 6.18-6.00 (m, 2H), 5.77 (d, J=15.1 Hz, 1H), 4.49 (br. s., 1H), 4.18-4.08 (m, 1H), 4.05-3.92 (m, 2H), 3.80-3.71 (m, 1H), 3.69 (s, 3H), 3.07 (d, J=10.5 Hz, 1H), 2.69 (d, J=12.0 Hz, 1H), 2.51-2.45 (m, 4H), 2.41 (br. s., 1H), 1.97 (t, J=11.7 Hz, 1H), 1.86-1.64 (m, 2H), 1.51-1.39 (m, 1H), 1.33 (s, 3H), 1.26 (s, 9H), 1.15 (d, J=6.3 Hz, 3H); LCMS (ESI, M+1): 674.3.